Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/16/2015)... Spirax Sarco, the leader in ... newly designed, state-of-the-art website in the first quarter ... promotes the Spirax Sarco brand, company capabilities, and ... a site visitor might be looking for including ... serviced, the latest company news, careers, and much ...
    (Date:4/16/2015)... FL (PRWEB) April 16, 2015 ... cap distribution and physician network in Europe and ... company has appointed Fernando Bermúdez, former Business Development ... , An industry veteran, Mr. Bermúdez’s professional achievements ... 75% in Spain, while also penetrating the Portuguese ...
    (Date:4/16/2015)... Streetsboro, Ohio (PRWEB) April 16, 2015 ... Safety Index, overexertion involving an outside source was ... injuries. This includes injuries related to lifting, pushing, ... $15.1 billion in direct costs. The David Round ... Round is committed to working hard to develop ...
    (Date:4/16/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company" ... pleased to announce that the Company will be presenting ... to be held in London, UK ... Mr. James Mellon , a director of Portage, ... key programs at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), ...
    Breaking Biology Technology:Spirax Sarco website has a new look 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4
    ... new data and program updates on cancer stem cell targeting ... ... /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology company discovering and ... be presenting new,findings and program updates related to its CD44, TROP-2, ...
    ... Ltd.,(SWX: ARPN) today announced that it will host ... 8.30am CET. In this conference call, a leading ... the area of anti-infective,drugs as well as the ... Advisory Committee. During that meeting, the committee discussed,product ...
    ... Chairman & CEO, Paul Willis,stated, "Just like his ... Whitacre has risen fast at Cypress Systems, Inc, last ... of operations.",Now Cypress and Whitacre are focusing their energy ... Americans -- and people around the,world -- to consume ...
    Cached Biology Technology:ARIUS presents new findings for anti-cancer antibody programs at AACR 2ARIUS presents new findings for anti-cancer antibody programs at AACR 3ARIUS presents new findings for anti-cancer antibody programs at AACR 4ARIUS presents new findings for anti-cancer antibody programs at AACR 5Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) 2Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) 3
    (Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
    (Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
    (Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
    Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
    ... we knowfor sure. Adding to a growing literature ... sperm ,function, it is now shown that one lactate dehydrogenase ... of ,work on this glycolytic enzyme had shown that it ... been ,only speculative. In an article on p. 26 Odet ...
    ... spring apples from the southern hemisphere as they enter the ... that has swept the industrialized world over the past couple ... complicated global process that has changed every aspect of how ... supermarkets in a country should bring with it the "cheap ...
    ... into the mechanisms that underlie long-term memory research with ... "The more we know about how long-term memory is ... in the brain, the more we are going to be ... professor of physiological science and neurobiology, whose new research appears ...
    Cached Biology News:July 2008 highlights 2Lost in the supermarket? 2Study of marine snail leads to new insights into long-term memory 2Study of marine snail leads to new insights into long-term memory 3Study of marine snail leads to new insights into long-term memory 4